Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Cell Genesys (CEGE) Slammed After Halting Trial Due To Deaths
More News related to CEGE
- Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer
- Cell Genesys Amends and Extends "Modified Dutch Auction" Tender Offer for up to $80 Million Aggregate Principal Amount of Its Convertible Debt Securities
- Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
- Cell Genesys Announces "Modified Dutch Auction" Tender Offer for up to $80 Million Aggregate Principal Amount of Its Convertible Debt Securities
- Cell Genesys Reports Third Quarter 2008 Financial Results
More News related to Insiders' Blog
- Cramer Says Illinois Tool Works (ITW) Should Buy Manitowoc (MTW)
- Cramer Thinks Nike (NKE) Should Buy Under Armour (UA)
- Citadel Down 13% in November And 47% For The Year
- What's Next for Google Stock? $200 or $400? (GOOG)
- Ford's (F), CEO, Alan Mulally, Addresses Capitol Hill
Shares of Cell Genesys, Inc. (Nasdaq: CEGE) are under heavy pressure this morning (-75%), following news the company terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in combination with Taxotere to Taxotere plus prednisone in patients with advanced-stage prostate cancer.
Cell Genesys ended the trial as recommended by its Independent Data Monitoring Committee which, in a routine safety review meeting held this week, observed an imbalance in deaths between the two treatment arms of the study.
Related Categories
FDAInsiders' Blog
Trader Talk
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
